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Abstract
Background Brain metastases from ovarian cancer are rare,
but their incidence is increasing. The purpose of this study
was to investigate the characteristics of brain metastases
from ovarian cancer, and to assess the efficacy of treatment
with gamma knife surgery (GKS).
Methods A retrospective review was performed of
patients with brain metastases from ovarian cancer
who were treated at the Tokyo Gamma Unit Center
from 2006 to 2010.
Results Sixteen patients were identified. Their median
age at diagnosis of brain metastases was 56.5 years,
the median interval from diagnosis of ovarian cancer
to brain metastases was 27.5 months, and the median num-
ber of brain metastases was 2. The median Karnofsky Perfor-
mance Score (KPS) at the first GKS was 80. The median
survival following diagnosis of brain metastases was
12.5 months, and 6-month and 1-year survival rates were
75 % and 50 %, respectively. The tumor control rate was
86.4 %. The KPS (<80 vs ≥80) and total volume of brain
metastases (<10 cm3 vs ≥10 cm3) were significantly associated
with survival according to a univariate analysis (p00.004 and
p00.02, respectively).
Conclusions The results of this study suggest that GKS is
an effective remedy and acceptable choice for the control of
brain metastases from ovarian cancer.
Keywords Ovarian cancer .Brainmetastases .Gammaknife
surgery . Tumor control rate
Introduction
Ovarian cancer is one of the most frequently diagnosed
gynecological malignancies [17]. Because symptoms are
usually not noticed in the early stages, ovarian cancer tends
to be diagnosed in the advanced stage and the prognosis,
therefore, is generally poor. Brain metastases from ovarian
cancer are rare, with their incidence ranging from 0.49 % to
6.1 % [3, 6, 7, 9, 14, 15, 20–22, 24, 25, 34, 37]. However,
recent studies have reported an increased incidence of brain
metastases from ovarian cancer [6, 15, 21]. The primary
reason for this increase is considered to be improvements
in chemotherapy, which have led to better control of the
primary malignancy and thus prolonged the life of the
patients. In addition, early detection has been enabled by
developments in imaging technologies [4, 12, 26]. Because
gamma knife surgery (GKS) for brain metastases has a high
local control rate and is minimally invasive [1, 2], it is
generally an effective remedy. Nevertheless, to our knowledge,
there have only been a few case reports and small series
studies of GKS for brain metastases from ovarian
cancer, and its efficacy remains unknown. In this study,
we investigated the characteristics of patients with brain
metastases from ovarian cancer, assessed the efficacy of
GKS for local tumor control, and analyzed prognostic
factors affecting patient survival.
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From March 2006 to January 2010, a total of 2603 patients
with brain metastases were treated with GKS at the Tokyo
Gamma Unit Center. The hospital’s database was searched
to identify those with brain metastases from ovarian cancer,
and the 16 identified patients were found to have been
treated with GKS a total of 31 times. One hundred and
nineteen tumors were treated in 31 GKS operations. Diag-
noses in all patients were made with gadolinium-enhanced
magnetic resonance imaging (MRI) with or without
contrast-enhanced computed tomography.
Stereotactic radiosurgery was performed with a Leksell
Gamma Knife model C (Elekta Instruments, Stockholm).
All patients underwent thin-slice gadolinium-enhanced MRI
after placement of the Leksell Model G stereotactic frame
(Elekta Instruments) and the treatment plans were created
using GammaPlan (Elekta Instruments). The dose delivered
to the margin of the tumor ranged from 10.1 to 22.32 Gy
(median 20.0 Gy). The maximum tumor dose ranged from
20.2 to 43.0 Gy (median 39.2 Gy).
After GKS, follow-up MRI was performed every 1–
3 months. We assessed changes in tumor size with
follow up MRI, and evaluated response to treatment
with the Response Evaluation Criteria in Solid Tumors
guideline [41]. At the 3 months following GKS, 66 of
119 tumors could be evaluated for tumor size, enabling
an analysis of the relationship between tumor size and
tumor control.
To assess the predictive factors for survival following
diagnosis of brain metastases, the following characteristics
were reviewed: age at diagnosis of brain metastases
(<60 years vs ≥60 years), interval from diagnosis of ovarian
cancer to brain metastases (<2 years vs ≥2 years), number of
brain metastases at first GKS (single vs multiple), total
volume of brain metastases at first GKS (<10 cm3
vs ≥10 cm3), Karnofsky Performance Score (KPS) at first
GKS (<80 vs ≥80), and treatment for brain metastases (GKS
alone vs combination therapy).
Statistical analysis
Statistical analysis was performed with a personal computer
running Stat View J-5.0 software (Abacus Concepts, Berkeley,
CA, USA). Survival was calculated from the date of
initial diagnosis of brain metastases until the date of
death or last contact. The Kaplan–Meier method was
used to calculate survival distributions. Differences in
survival were analyzed using a log-rank test; p<0.05
was considered significant.
Results
From March 2006 to January 2010, a total of 2,603 patients
with brain metastases were treated with GKS at the Tokyo
Gamma Unit Center; 16 (0.6 %) of these patients had brain
metastases from ovarian cancer. Two patients were treated
with whole-brain radiotherapy (WBRT) before GKS (cases
4 and 9), two underwent surgical resection before GKS
(cases 6 and 10), one was treated with WBRT and surgical
resection before GKS (case 12), and one was treated with
stereotactic radiotherapy before GKS (case 5). Patient char-
acteristics of 16 patients are shown in Table 1.
The median age of the patients diagnosed with ovarian
cancer and brain metastases was 53 years (range,
38–73 years) and 56.5 years (range, 44–75 years), respec-
tively. The median interval from diagnosis of ovarian cancer
to brain metastases was 27.5 months (range, 0–84 months),
and the median number of brain metastases was 2 (range, 1–
18). At the time of first GKS, the median KPS was 80
(range, 50–100).
At last follow-up, six patients were alive and ten patients
had died. The overall median survival from the time of first
GKS was 9.5 months (range, 3–29 months), from diagnosis
of brain metastases was 12.5 months (range, 4–34 months),
and from diagnosis of ovarian cancer was 46 months (range,
14–97 months). The 6-month and 1-year survival rates from
the time of diagnosis of brain metastases were 75 % and
50 %, respectively. The 6-month and 1-year survival rates
from the time of first GKS were 69 % and 31 %,
respectively.
At 3 months following GKS, 66 tumors could be evalu-
ated for tumor size; 17 tumors were in complete remission
(CR), 40 showed partial response (PR), 8 stable disease, and
1 progressive disease (PD). The tumor of PD became a PR by
performing additional GKS. The tumor control rate ([CR +
PR]/total number of tumors×100) was 86.4 %. When tumors
were classified by size, namely <10 mm, 10–20 mm, 20–
30 mm, and >30 mm, the tumor control rates were 89.7 %,
86.7 %, 80.0 %, and 50.0 %, respectively. No tumor hemor-
rhaged after GKS.
A total of nine patients (56.3 %) were found to have new
brain metastases during the follow-up period. The interval
between the date receiving initial GKS and the date of
appearance of a new distant lesion was calculated. The
median new distant-lesion-free survival period was
4.5 months (range, 1–15 months).
Age at diagnosis of brain metastases, interval to brain
metastases, number of brain metastases at first GKS, and
treatment for brain metastases were not associated with
survival following brain metastases. The KPS at first GKS
and total tumor volume at first GKS were associated with
survival and were important predictors of survival according
to a univariate analysis (p00.004 and p00.02, respectively).
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The median overall survival for the nine patients with KPS ≥80
was significantly longer than that of the seven patients with
KPS <80 (17.0 vs 8.0 months, p00.004). The median overall
survival for the ten patients with total volume of brain metas-
tases <10 cm3 was significantly longer than that of the six
patients with total volume of brain metastases ≥10 cm3 (16.5
vs 7.0 months, p00.02). The number of brain metastases was
not significantly associated with survival, but the median over-
all survival for the six patients with a single metastases tended
to be longer than that of the ten patients with multiple metas-
tases (16.5 vs 9.5 months, p00.05) (Table 2).
Discussion
Ovarian cancer is one of the most frequent causes of malig-
nancy in women [17]. The majority of patients are discov-
ered with advanced disease because very few symptoms are
observed in the early stages of ovarian cancer. Brain metas-
tases from ovarian cancer is uncommon—its incidence
ranges from 0.49 % to 6.1 % [3, 6, 7, 9, 14, 15,
20–22, 24, 25, 34, 37]. Pectasides et al. [35] reported
an estimated incidence of 1.01 % in a review of 22,240
patients with ovarian cancer. However, recent studies
have suggested that the incidence of brain metastases
from ovarian cancer is increasing [6, 15, 21]. Platinum-
based chemotherapy has led to improved survival rates
among ovarian cancer patients, but these agents have
poor blood–brain barrier permeability and brain metas-
tases have thus become a late manifestation of ovarian
cancer. The development of better imaging techniques
has also enabled diagnosis on the basis of smaller brain
metastatic lesions [4, 12, 26].
In the review of brain metastases from ovarian cancer by
Pectasides et al. [35], single brain metastases occurred in
43.8 % of patients, multiple metastases in 51.6 %, and
leptomeningeal metastases alone in 4.6 %. In this study,
37.5 % of patients had single metastases, 62.5 % had mul-
tiple metastases, and no patient had leptomeningeal
metastases.
Data from the literature indicate that the median age at
diagnosis of ovarian cancer ranges from 51 to 59.5 years,
and the median age at diagnosis of brain metastases ranges
from 52.5 to 58 years. The median interval to brain metas-
tases ranges from 14.5 to 46 months [3, 5–7, 9, 14, 15,
20–22, 24, 25, 34, 37] (Tables 3, 4). The results from our
patients support these data.
Brain metastases from ovarian cancer represent a late
manifestation; once brain metastases occur, survival is
generally poor, regardless of treatment [14, 21]. Therapies
for brain metastases include surgical resection, radiotherapy,
chemotherapy, or their combination. Cohen et al. [7]
reported that the combination of surgical resection and
WBRT resulted in longer survival than WBRT alone or
surgical resection alone (median survival of 23 months,
5 months, and 7 months, respectively). Anupol et al. [3]
reported that combined treatment with radiation and surgical
resection with or without chemotherapy led to a good prog-
nosis in patients with brain metastases. Other authors have
also supported an aggressive combination therapy approach
Table 2 Univariate analysis of
survival following diagnosis of
brain metastases






Age at diagnosis of brain metastases
<60 years 10 12.0 0.1841
≥60 years 6 13.0
Interval to brain metastases
<2 years 6 14.0 0.5592
≥2 years 10 12.0
Number of brain metastases at first GKS
Single 6 16.5 0.0507
Multiple 10 9.5
Total volume of brain metastases at first GKS
<10 cm3 10 16.5 0.0203
≥10 cm3 6 7.0
KPS at first GKS
<80 7 8.0 0.0042
≥80 9 17.0
Treatment for brain metastases
GKS alone 10 9.5 0.2020
Combination therapy 6 19.0
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[11, 15, 18, 22, 25, 34, 36, 37]. In our study, treatment for
brain metastases was not significantly associated with
survival, but the median overall survival for the six patients
treated with combination therapy tended to be longer than that
of the ten patients treated GKS alone (19.0 vs 9.5 months,
p00.2). Our result also supports combination therapy.
The efficacy of systemic chemotherapy for brain metas-
tases from ovarian cancer remains controversial. Cooper et
al. [8] reported a response in three patients with brain
metastases treated with carboplatin, Melichar et al. [27]
reported a response in a patient treated with cisplatin and
gemcitabine, and Watanabe et al. [42] reported a response in
a patient treated with carboplatin and docetaxel. To our
knowledge, the only literature providing support for the
efficacy of chemotherapy for brain metastases from ovarian
cancer are case reports and small case series.
GKS for brain metastases has become increasingly common
because GKS is a noninvasive modality that provides good
local control [1, 2]. Muacevic et al. [30] reported that there were
no significant difference in a 1-year local tumor control rate and
1-year survival rate between patients treated with GKS alone
for solitary brain metastases and those who were treated with
surgical resection plus WBRT. O’Neil et al. [32] reported that
there was no significant difference in the 1-year survival rate
between patients treated with GKS and those who underwent
surgical resection (62 % vs 56 %), and GKS resulted in signif-
icantly better local control compared with surgical resection
(recurrence rate of 0 % vs 58 %).
GKS for brain metastases from ovarian cancer was first
reported by Kawana et al. [19] in 1997. They described a
case of multiple brain metastases successfully treated by a
multimodality treatment including GKS. Lee et al. [24]
reported that GKS for brain metastases from ovarian cancer
resulted in longer survival compared with WBRT (median
survival of 29 vs 6 months), and Corn et al. [10] reported
that radiosurgery led to a more frequent complete remission
(40 % vs 29 %), and higher 2-year survival rate (60 % vs
15 %) than WBRT alone. Kim et al. [20] reported that
treatment modalities including GKS were associated with
survival and that patients with brain metastases had better
outcomes with GKS. However, these reports are all from
small series of patients and no prospective studies of GKS
for brain metastases from ovarian cancer have been con-
ducted. Our study is a retrospective study, but it is the
second largest study of GKS for brain metastases from
ovarian cancer to be performed. Monaco et al. [28] reported
on 27 patients with brain metastases from ovarian cancer
and endometrial carcinoma treated with GKS. The median
survival after brain metastases was 7 months and the 1-year
survival rate was 22 %. All tumors were controlled. They
suggested that GKS was an acceptable choice for brain
metastases, but their report included the results of the six
patients with brain metastases from endometrial carcinoma.
In our study, the tumor control rate was 86.4 % and no
tumors hemorrhaged after GKS. Our results show tumor
control rates comparable to those of lung cancers (72.7–
94 %) [16, 33, 38], breast cancers (90–94 %) [13, 23, 31],
and renal cell cancer (82.6–96 %) [29, 39, 40]. GKS for
brain metastases from ovarian cancer provides good local
control with few side effects.
Several reports have identified predictive factors for brain
metastases from ovarian cancer. KPS, number of brain me-
tastases, recursive partitioning analysis, and extracranial
metastases have all been associated with survival [3, 5, 9,
18, 20, 25]. In our study, the KPS ≥80 % and total volume of
brain metastases <10 cm3 were factors to be significantly
associated with longer survival (p00.004 and p00.02,
respectively). Age at diagnosis of brain metastases, interval
to brain metastases, number of brain metastases, and treat-
ment for brain metastases were not associated with survival.
However, patients with a single metastases tended to survive
longer than patients with multiple metastases (p00.05).
Only a limited number of patients with brain metastases
from ovarian cancer have been treated with GKS to date,
and prospective data are lacking. However, the results of
this study indicate that GKS for brain metastases from
ovarian cancer provides good local control with few side
effects. GKS thus appears to be an acceptable choice for the
control of brain lesions in ovarian cancer patients. Combi-
nation therapy improves prognosis for patient with brain
metastases from ovarian cancer. GKS can become one
modality of combination therapy.
Conclusions
Brain metastases from ovarian cancer are rare, but their
incidence is increasing as patient survival has been extended
by successful platinum-based chemotherapy and improved
imaging techniques have enabled the identification of
smaller lesions. In our study, the median survival from brain
metastases was 12.5 months, and the local control rate was
86.4 %. The KPS and total volume of brain metastases were
important factors predictive of survival. Our results suggest
that GKS is an acceptable therapy for brain metastases from
ovarian cancer.
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Comment
This is an important paper on radiosurgery for brain metastases caused
by ovarian cancer. Brain metastases caused by ovarian cancer are rare.
Yet, with improving oncological care, they are encountered more
frequently. Not surprisingly, the results following radiosurgery for
those brain metastases are comparable to the results for brain metasta-
ses caused by other carcinomas. Local tumor control following radio-
surgery for brain metastases seems to be independent of tumor
histology, whereas survival seems to depend on tumor histology and
progression of the systemic disease [1].
1. Mindermann T (2005) Tumor recurrence and survival following
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